GlobeNewswire Inc.··NaRevolution Medicines Advances KRAS G12D Lung Cancer Drug With 52% Response Rate
Revolution Medicines reports promising Phase 1 data for zoldonrasib, showing 52% response rate in previously treated KRAS G12D lung cancer patients with manageable safety profile.
RVMDRVMDWPhase 1 clinical trialoncology